Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

2020 ◽  
Vol 21 (5) ◽  
pp. 645-654 ◽  
Author(s):  
José Trigo ◽  
Vivek Subbiah ◽  
Benjamin Besse ◽  
Victor Moreno ◽  
Rafael López ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Small Cell ◽  
Line Treatment ◽  
Second Line ◽  
Phase 2 ◽  
Small Cell Lung ◽  
Open Label ◽  
Open Label Phase ◽  
Basket Trial

TIGER 1: A randomized, open-label, phase 2/3 study of rociletinib (CO-1686) or erlotinib as first-line treatment for EGFR-mutant non-small cell lung cancer (NSCLC).

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. TPS8108-TPS8108 ◽  
Author(s):  
D. Ross Camidge ◽  
Juergen Wolf ◽  
Jason B. Litten ◽  
Linda A Higashi ◽  
Jeffrey D. Isaacson ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell ◽  
Line Treatment ◽  
Phase 2 ◽  
Small Cell Lung ◽  
First Line ◽  
Open Label ◽  
Open Label Phase ◽  
Egfr Mutant ◽  
First Line Treatment

scholarly journals ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC)

Cancer ◽  
2018 ◽  
Vol 124 (24) ◽  
pp. 4667-4675 ◽  
Author(s):  
Daniel Morgensztern ◽  
Manuel Cobo ◽  
Santiago Ponce Aix ◽  
Pieter E. Postmus ◽  
Conrad R. Lewanski ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Line Treatment ◽  
Second Line ◽  
Phase 2 ◽  
Small Cell Lung ◽  
Phase 2 Study ◽  
Randomized Phase 2
Sign in / Sign up

Export Citation Format

Share Document